Loading
companiesCompany
C2i Genomics
C2i Genomics built a blood test that reads the whole genome of tumour DNA fragments to detect leftover cancer after treatment; Veracyte bought the company in 2024 and now sells the approach as TrueMRD.
Overview
C2i Genomics, founded in New York with research roots at the New York Genome Center and the Weizmann Institute, developed a whole-genome approach to minimal residual disease (MRD) detection. Rather than tracking a small targeted panel, it sequences the tumour genome to define thousands of somatic variants and applies AI pattern recognition to low-pass whole-genome sequencing of plasma cell-free DNA, giving sensitive detection from a single blood tube. Veracyte announced a definitive agreement to acquire C2i on 8 January 2024 for $70 million in Veracyte shares at closing plus up to $25 million in performance milestones, extending its diagnostics platform into MRD monitoring. The technology now underpins Veracyte's TrueMRD platform, whose first test, for muscle-invasive bladder cancer, is available to order in the United States, with more cancers planned.
Headquarters
New York, NY, US
Funding
All startupsAcquiredAcquired by Veracyte (Decipher)
Investors not recorded; see the round sources.
Rounds on record
| Round | Year | Amount | Source |
|---|---|---|---|
| Acquisition · $70 million in Veracyte shares at closing plus up to $25 million in milestone payments over two years; definitive agreement announced 8 January 2024. | 2024 | $70M | sec.gov |
Amounts only where the cited source states them. Rounds without a public source are not listed.
Type
Stage
Acquired
Notes
top- c2i-genomics.com redirects to Veracyte. Pre-acquisition venture rounds not sourced. Completion date of the acquisition not separately verified; the 8-K covers the definitive agreement.
Similar pages
- CompanyExai Bio
Shares Casdin Capital, Liquid biopsy (ctDNA).
- PersonNitzan Rosenfeld
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyPersonalis (Tempus)
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyHaystack Oncology
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- CompanyIsabl
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing.
- CompanyValius Sciences
Shares Whole-exome & whole-genome sequencing, Liquid biopsy (ctDNA).
- IdeaPush residual disease detection a hundredfold deeper with whole-genome methods
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).
- Key paperTRACERx 421: the full-cohort picture of how lung cancer evolves and which subclones drive relapse
Shares Whole-exome & whole-genome sequencing, MRD / molecular residual disease testing, Liquid biopsy (ctDNA).